Compare Quantumscape Corp (QS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs BIO-TECHNE Corp — how do they compare? Quantumscape Corp trades at $5.24 (market cap $3.44B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 3.3× Quantumscape Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| QS | TECH | |
|---|---|---|
Market Cap | $3.44B | $11.34B |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $72.48 |
52-Week Low | $4.89 | $43.31 |
Enterprise Value | $2.65B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $5.59, up 2.01% today but near its 52-week low, with a bearish technical signal from moving averages. The company reported a net loss of $435.05M for 2025, with negative ROE and ROA, and has no revenue as it develops solid-state batteries. Recent news highlights insider sales and delayed commercialization to 2029, while institutional interest includes new positions from Bank of New York Mellon (September 3, 2026).
Outlook remains high-risk due to pre-revenue status and execution delays, with analyst consensus cautious (72.7% hold, 27.3% sell). Opportunities hinge on battery technology success, but investors face substantial volatility and competitive threats from automakers. Cash flow trends show reliance on financing, with net cash flow turning positive in 2025 at $85.27M after prior losses.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
